Synonyms: AZD 2014 | AZD-2014 | AZD2014 | cc-551
Compound class:
Synthetic organic
Comment: Vistusertib (AZD2014) is a selective inhibitor of Mammalian target of rapamycin (mTOR) serine/ threonine kinase. This compound is included in AstaZeneca's Open Innovation Pharmacology Toolbox.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
AZD2014 inhibitory effect (IC50) of the transcriptional complexes mTORC1 and mTORC2 are reported as 200nM and 80nM respectively [5]. mTORC1 acts as a nutrient/energy/redox sensor and controls protein synthesis and has been related to ageing in experiments using model organisms [3-4,6]. mTORC2 regulates cellular metabolism and the cytoskeleton [7] and may play a role in the regulation of autophagy [2,9]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|